(Q53218072)

12 May 2018

title

Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. (English)

1 reference

12 May 2018

1 reference

1 reference

1 reference

Blisse Vakkalagadda

1

1 reference

12 May 2018

Charles Frost

2

1 reference

12 May 2018

Wonkyung Byon

3

1 reference

12 May 2018

Rebecca A Boyd

4

1 reference

12 May 2018

Jessie Wang

5

1 reference

12 May 2018

Donglu Zhang

6

1 reference

12 May 2018

Zhigang Yu

7

1 reference

12 May 2018

Clapton Dias

8

1 reference

12 May 2018

Andrew Shenker

9

1 reference

12 May 2018

Frank LaCreta

10

1 reference

12 May 2018

publication date

1 April 2016

1 reference

12 May 2018

American journal of cardiovascular drugs

published in

1 reference

12 May 2018

volume

16

1 reference

12 May 2018

issue

2

1 reference

12 May 2018

page(s)

119-127

1 reference

12 May 2018

https://scigraph.springernature.com/pub.10.1007/s40256-015-0157-9

exact match

0 references

cites work

Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood [...]

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

Apixaban or enoxaparin for thromboprophylaxis after knee replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

Apixaban versus enoxaparin for thromboprophylaxis after hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

Apixaban in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

Apixaban versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

Oral apixaban for the treatment of acute venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

Apixaban metabolism and pharmacokinetics after oral administration to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

Tissue distribution and elimination of [14C]apixaban in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

Sulfation of o-demethyl apixaban: enzyme identification and species comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

Characterization of efflux transporters involved in distribution and disposition of apixaban.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

Membrane transporters in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

The drug efflux-metabolism alliance: biochemical aspects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

General derivation of the equation for time to reach a certain fraction of steady state.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

Pharmacokinetic interactions with rifampicin : clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

Model-based exposure-response analysis of apixaban to quantify bleeding risk in special populations of subjects undergoing orthopedic surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

Pharmacokinetics and metabolic drug interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-015-0157-9

10.1007/S40256-015-0157-9

21 January 2018

Identifiers

DOI

1 reference

12 May 2018

PubMed ID

26749408

1 reference

12 May 2018